Financings
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.
Executive Summary
- Onco-Innovations Limited executed a term sheet for a non-brokered private placement with a notional subscription amount of approximately CAD$5,000,000.
- The company is abandoning its previously announced Listed Issuer Financing Exemption (LIFE) offering filed on June 19, 2026, in favor of a complex "Sharing Agreement" structure.
- The offering consists of 6,764,070 units at a notional price of CAD$0.7392 per unit, comprising common shares and warrants.
- Securities are delivered into escrow and released to investors upon closing, meaning immediate dilution occurs.
- No immediate cash proceeds are available to the company. Economic interest is determined via 18 monthly settlement tranches based on the monthly VWAP relative to a benchmark price of CAD$0.9691.
- If the settlement price exceeds the benchmark, the company receives >100% of the monthly amount; if below, it receives <100%. There is no increase in shares issued if the price declines.
- Subscription is to be satisfied in cash or via a portfolio of UK government bonds at market value, with investors assuming market/FX risk.
- A corporate finance fee of CAD$400,000 is payable in cash or 541,126 Units at the company's election.
- Proceeds are designated for advancing the ONC010 program, SynoGraph™ platform development, and general working capital.
- Concurrently, the company announced the initiation of polymer process development and analytical characterization for ONC010 with Nanosoft Polymers to support future GMP manufacturing.
Material Impact
- The financing structure is highly atypical for a preclinical-stage biotechnology company. By issuing shares immediately but deferring cash settlement over 18 months, the company provides zero near-term liquidity to address its existing cash crunch.
- The performance-based settlement mechanism ties future cash inflows directly to stock price appreciation. Given the company's lack of revenue and preclinical status, achieving a sustained VWAP above the CAD$0.9691 benchmark is uncertain.
- The structure is inherently dilutive upon closing due to immediate share issuance, while offering asymmetric downside risk to the company's cash runway if the stock trades below the benchmark.
- The CAD$400,000 corporate finance fee further erodes the net capital efficiency of the transaction.
- The concurrent R&D update regarding polymer process development is a standard IND-enabling milestone and does not offset the financing's structural drawbacks.
ONCO · Price
Company Overview
- Onco-Innovations Limited is a preclinical-stage oncology company developing ONC010, a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor targeting solid tumors.
- The company operates a wholly-owned subsidiary, Inka Health Corp., which is advancing the SynoGraph™ AI-driven precision oncology platform for real-world evidence generation and external control arms.
- Key development partners include Dalton Pharma Services (manufacturing), Nucro-Technics (preclinical/toxicology), Avance Clinical (clinical start-up), and strategic collaborators such as AstraZeneca and OneMedNet.
- The company holds an exclusive worldwide license to patented PNKP inhibitor technology and is focused on transitioning from preclinical research to first-in-human clinical trials.
More from ONCO-INNOVATIONS LIMITED
Jun 30, 2026 · 18:00